Press release
Ebola Vaccine Market - Global Industry Insights, 2017-2025
Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.
Ask for detailed Sample of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1365
According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology.
Ebola Vaccine Market Taxonomy:
On the basis of virus strain, the global Ebola vaccine market is segmented into:
Recombinant vesicular stomatitis virus-Zaire Ebola virus
Chimpanzee Adeno virus type 3-Zaire Ebola virus
Adeno virus serotype 26- Zaire Ebola Virus
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1365
GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ebola Vaccine Market - Global Industry Insights, 2017-2025 here
News-ID: 999248 • Views: …
More Releases from Biotechnology by CMI
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Multiple Sclerosis Therapeutics Market – Offering Long-term Disease Management
Multiple sclerosis (MS) is a disabling autoimmune disease affecting the brain and the spinal cord, eventually causing nerve deterioration or permanent damage. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression…
Oncology Biosimilars Market-Opportunity Analysis, 2017-2025
Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries…
Kidney Transplant Holds The Maximum Share Of Organ Transplant Market Due To Risi …
Organ transplantation is the surgical operation in which a healthy organ is removed from one person and transplanted to another person whose organ is failed or damaged. In the organ transplantation, the donated organ may be from living donor, deceased donor, or from an animal. Whereas in some cases an artificial organ is used in the transplantation procedure. Organ transplantation gives new life to the individual with damaged or failed…
Orthobiologics Market - Global Industry Insights, Trends, Outlook, and Opportuni …
Orthobiologics are substances used to heal injuries such as fractures and injured muscles, ligaments, and tendons within a short period of time. Orthobiologics are made from substances that naturally occur in the body. Some examples of orthobiologics are bone grafts, autologous blood, autologous conditioned serum, platelet rich plasma, growth factors, and stem cells.
Increasing prevalence of injury and facture due to falls and road accidents are expected to augment growth of…
More Releases for Ebola
Ebola Virus Vaccine Market 2022 | Detailed Report
The Ebola Virus Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the Ebola…
Ebola Vaccine Market Opportunity Analysis, 2018-2026
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus…
Ebola Treatment Market Rugged Expansion Foreseen by 2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,…
Growing Trends in Ebola Drug and Vaccine Market
The rising threat of a global Ebola pandemic is the major driver for the global Ebola drug and vaccines market, according to a new report from Transparency Market Research. The report, titled ‘Ebola Drug and Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecasts 2016 – 2024,’ presents a solid outline of the historical development of the market, in addition to comprehensive information about the market’s present…
Ebola Virus Vaccine Market & Pipeline Insight
Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in 1976. The infection caused due to ebola virus originates from four different strains of ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of ebola virus are Fruit bats, which…
combit Employees Support Ebola Victims and Syrian Refugees
Constance/Germany, 12/02/2014 – Among the numerous reports on crisis regions, those that remain particularly etched in our memory are the images of the critically ill people in West Africa who are infected with Ebola and of the suffering of the Syrian refugees. For that reason, the employees of the software company combit in Constance have decided to help. The fight against the Ebola virus is costly, and the Syrian health…
